Macquarie Group
INSY

Macquarie Group’s Insys Therapeutics, Inc. INSY Stock Holding History

Macquarie Group’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,200
Closed -$12K – 2510
2017
Q4 		$12K Buy
+1,200
New +$7.85K ﹤0.01% 2248
2016
Q2 		– Sell
-434,385
Closed -$6.95M – 1670
2016
Q1 		$6.95M Buy
434,385
+116,384
+37% +$2.21M 0.01% 637
2015
Q4 		$9.1M Buy
318,001
+97,250
+44% +$2.69M 0.02% 570
2015
Q3 		$6.28M Buy
+220,751
New +$8.12M 0.01% 660

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Macquarie Group's INSY Position: Q1 2018 in Review

Macquarie Group sold out of Insys Therapeutics, Inc. (INSY) in Q1 2018, closing a stake of 1,200 shares — an estimated $12K sold.

Macquarie Group first reported a position in INSY in Q3 2015 and held it in 4 quarters. The position peaked at $9.1M in Q4 2015. 110 funds tracked by Wall St. Rank hold INSY as of Q1 2018.

  • Macquarie Group reported no remaining Insys Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Macquarie Group sold 1,200 Insys Therapeutics, Inc. shares in Q1 2018, an estimated $12K.
  • Macquarie Group first reported a position in Insys Therapeutics, Inc. in Q3 2015 and held it in 4 quarters.
  • Macquarie Group's Insys Therapeutics, Inc. position peaked at $9.1M in Q4 2015.
  • 110 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.